AMN Healthcare Services Inc (AMN) stock
Close on Nov 13, 2026Market cap $1.47BP/E 13.8Yield –
Earnings
AMN Healthcare Services's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of AMN Healthcare Services's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $717.00M | +13.1% | $0.83 | $1.16 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | $634.00M | -7.8% | $0.76 | $0.39 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | $658.20M | -11.2% | -$3.02 | $0.30 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025during market hours | $690.00M | -16.0% | -$0.03 | $0.45 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 20, 2025during market hours | $735.00M | -10.1% | -$4.90 | $0.75 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024during market hours | $688.00M | -19.4% | $0.18 | $0.61 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024during market hours | $741.00M | -25.2% | $0.42 | $0.98 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024during market hours | $821.00M | -27.1% | $0.45 | $0.97 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 15, 2024during market hours | $818.00M | -27.4% | $0.33 | $1.32 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023during market hours | $853.50M | -25.1% | $1.39 | $1.97 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023during market hours | $991.30M | -30.5% | $1.55 | $2.38 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023during market hours | $1.13B | -27.5% | $2.02 | $2.49 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 16, 2023during market hours | $1.13B | -17.4% | $1.88 | $2.48 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022during market hours | $1.14B | +29.7% | $2.10 | $2.57 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022during market hours | $1.43B | – | $2.77 | $3.31 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022during market hours | $1.55B | – | $3.09 | $3.49 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 17, 2022during market hours | $1.36B | – | $2.42 | $2.95 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021during market hours | $878.00M | – | $1.54 | $1.73 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 18, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020during market hours | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020during market hours | – | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 11, 2020during market hours | – | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Jan 29, 2020during market hours | – | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Oct 31, 2019during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
AMN Healthcare Services's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Consolidated revenueGAAP | Q4 FY2026 | $655.00M – $670.00M | – | New | Nov 5, 2026 |
| Gross marginGAAP | Q4 FY2026 | 25.7% – 26.2% | – | New | Nov 5, 2026 |
| Operating marginGAAP | Q4 FY2026 | -0.1% – 0.5% | – | New | Nov 5, 2026 |
| Adjusted EBITDA marginnon-GAAP | Q4 FY2026 | 5.8% – 6.3% | – | New | Nov 5, 2026 |
| SG&A as percentage of revenueGAAP | Q4 FY2026 | 21.2% – 21.7% | – | New | Nov 5, 2026 |
Guidance vs results
The last range AMN Healthcare Services gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2025 | Revenue | $610.00M – $625.00M | $634.00M | Above range |
| Q3 FY2025 | Revenue growth | -14% – -11% | -7.85% | Above range |
| Q2 FY2025 | Revenue | $645.00M – $660.00M | $658.20M | Within range |
| Q2 FY2025 | Revenue growth | -13% – -11% | -11.17% | Within range |
| Q1 FY2025 | Revenue | $660.00M – $680.00M | $690.00M | Above range |
| Q4 FY2024 | Revenue | $685.00M – $705.00M | $735.00M | Above range |
| Q3 FY2024 | Revenue | $660.00M – $680.00M | $688.00M | Above range |
| Q3 FY2024 | Revenue growth | -23% – -20% | -19.39% | Above range |
| Q2 FY2024 | Revenue | $730.00M – $750.00M | $741.00M | Within range |
| Q1 FY2024 | Revenue | $810.00M – $830.00M | $821.00M | Within range |
| Q1 FY2024 | Revenue growth | -28% – -26% | -27.09% | Within range |
| Q4 FY2023 | Revenue | $790.00M – $810.00M | $818.00M | Above range |
| Q3 FY2023 | Revenue | $840.00M – $860.00M | $853.50M | Within range |
| Q1 FY2023 | Revenue | $1.10B – $1.13B | $1.13B | Within range |
| Q4 FY2022 | Revenue | $1.05B – $1.08B | $1.13B | Above range |
| Q3 FY2022 | Revenue | $1.08B – $1.11B | $1.14B | Above range |
| Q2 FY2022 | Revenue | $1.34B – $1.38B | $1.43B | Above range |
| Q1 FY2022 | Revenue | $1.48B – $1.52B | $1.55B | Above range |
| Q4 FY2021 | Revenue | $1.13B – $1.15B | $1.36B | Above range |
Guidance history
Every forecast AMN Healthcare Services put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Adjusted EBITDA margin | Q4 FY2026 | 5.8% – 6.3% | New |
| Nov 5, 2026 | Gross margin | Q4 FY2026 | 25.7% – 26.2% | New |
| Nov 5, 2026 | Operating margin | Q4 FY2026 | -0.1% – 0.5% | New |
| Nov 5, 2026 | SG&A as percentage of revenue | Q4 FY2026 | 21.2% – 21.7% | New |
| Nov 5, 2026 | Consolidated revenue | Q4 FY2026 | $655.00M – $670.00M | New |
| Nov 6, 2025 | Gross margin | Q4 FY2025 | 25.5% – 26% | New |
| Nov 6, 2025 | Operating margin | Q4 FY2025 | 0.2% – 0.8% | New |
| Nov 6, 2025 | depreciation | Q4 FY2025 | $17.00M | New |
| Nov 6, 2025 | diluted average shares outstanding | Q4 FY2025 | 38.9 | New |
| Nov 6, 2025 | SG&A as percentage of revenue | Q4 FY2025 | 20% – 20.5% | New |
| Nov 6, 2025 | Adjusted EBITDA margin | Q4 FY2025 | 6.8% – 7.3% | New |
| Nov 6, 2025 | adjusted tax rate | Q4 FY2025 | 28% | Raised |
| Nov 6, 2025 | depreciation in cost of revenue | Q4 FY2025 | $2.50M | Lowered |
| Nov 6, 2025 | non-cash amortization expense | Q4 FY2025 | $19.00M | Raised |
| Nov 6, 2025 | share-based compensation expense | Q4 FY2025 | $6.50M | Lowered |
| Nov 6, 2025 | integration and other expenses | Q4 FY2025 | $3.00M | Lowered |
| Nov 6, 2025 | interest expense | Q4 FY2025 | $11.50M | Raised |
| Nov 6, 2025 | Labor disruption revenue | Q4 FY2025 | $100.00M | Lowered |
| Nov 6, 2025 | Revenue year-over-year growth | Q4 FY2025 | -3% – -1% | New |
| Nov 6, 2025 | Nurse and Allied Solutions segment revenue year-over-year growth | Q4 FY2025 | +1% – +3% | Raised |
| Nov 6, 2025 | Consolidated revenue | Q4 FY2025 | $715.00M – $730.00M | New |
| Nov 6, 2025 | Physician and Leadership Solutions segment revenue year-over-year growth | Q4 FY2025 | -4% – -2% | Lowered |
| Nov 6, 2025 | Technology and Workforce Solutions segment revenue year-over-year growth | Q4 FY2025 | -16% – -14% | Lowered |
| Aug 7, 2025 | Gross margin | Q3 FY2025 | 28.7% – 29.2% | New |
| Aug 7, 2025 | Operating margin | Q3 FY2025 | 6% – 6.5% | New |
| Aug 7, 2025 | Adjusted EBITDA margin | Q3 FY2025 | 7.7% – 8.2% | New |
| Aug 7, 2025 | SG&A as percentage of revenue | Q3 FY2025 | 23% | New |
| Aug 7, 2025 | Nurse and Allied Solutions segment revenue | Q3 FY2025 | -14% – -11% | Lowered |
| Aug 7, 2025 | Physician and Leadership Solutions segment revenue | Q3 FY2025 | -4% – -2% | Raised |
| Aug 7, 2025 | Technology and Workforce Solutions segment revenue | Q3 FY2025 | -14% – -12% | Lowered |
| Aug 7, 2025 | Consolidated revenue | Q3 FY2025 | $610.00M – $625.00M | New |
| Aug 7, 2025 | Labor disruption revenue | Q3 FY2025 | $5.00M | Lowered |
| Aug 7, 2025 | Revenue in the third quarter of 2025 | Q3 FY2025 | -11% – -9% | New |
| May 8, 2025 | Gross margin | Q2 FY2025 | 28.5% – 29% | New |
| May 8, 2025 | Operating margin | Q2 FY2025 | -0.7% – 0% | New |
| May 8, 2025 | diluted average shares outstanding | Q2 FY2025 | 38.6 | New |
| May 8, 2025 | SG&A as percentage of revenue | Q2 FY2025 | 23.2% – 23.7% | New |
| May 8, 2025 | Adjusted EBITDA margin | Q2 FY2025 | 7.8% – 8.3% | New |
| May 8, 2025 | adjusted tax rate | Q2 FY2025 | 28% | Raised |
| May 8, 2025 | depreciation | Q2 FY2025 | $19.00M | New |
| May 8, 2025 | depreciation in cost of revenue | Q2 FY2025 | $2.00M | Lowered |
| May 8, 2025 | non-cash amortization expense | Q2 FY2025 | $20.00M | Raised |
| May 8, 2025 | share-based compensation expense | Q2 FY2025 | $11.00M | Lowered |
| May 8, 2025 | integration and other expenses | Q2 FY2025 | $3.00M | Lowered |
| May 8, 2025 | interest expense | Q2 FY2025 | $11.50M | Raised |
| May 8, 2025 | Revenue | Q2 FY2025 | -13% – -11% | New |
| May 8, 2025 | Consolidated revenue | Q2 FY2025 | $645.00M – $660.00M | New |
| May 8, 2025 | labor disruption revenue | Q2 FY2025 | $16.00M | Lowered |
| Feb 20, 2025 | Gross margin | Q1 FY2025 | 28.1% – 28.6% | New |
| Feb 20, 2025 | Operating margin | Q1 FY2025 | -0.3% – 0.4% | New |
| Feb 20, 2025 | SG&A as percentage of revenue | Q1 FY2025 | 22.2% – 22.7% | New |
| Feb 20, 2025 | Adjusted EBITDA margin | Q1 FY2025 | 7.7% – 8.2% | New |
| Feb 20, 2025 | Consolidated revenue | Q1 FY2025 | $660.00M – $680.00M | New |
| Nov 7, 2024 | Adjusted EBITDA margin | Q4 FY2024 | 9.2% – 9.7% | New |
| Nov 7, 2024 | Gross margin | Q4 FY2024 | 29.3% – 29.8% | New |
| Nov 7, 2024 | Operating margin | Q4 FY2024 | 1.8% – 2.5% | New |
| Nov 7, 2024 | SG&A as percentage of revenue | Q4 FY2024 | 21.5% – 22% | New |
| Nov 7, 2024 | Consolidated revenue | Q4 FY2024 | $685.00M – $705.00M | New |
| Aug 8, 2024 | Gross margin | Q3 FY2024 | 30.7% – 31.2% | New |
| Aug 8, 2024 | Operating margin | Q3 FY2024 | 2.1% – 2.9% | New |
| Aug 8, 2024 | diluted average shares outstanding | Q3 FY2024 | 38.3 | New |
| Aug 8, 2024 | SG&A as percentage of revenue | Q3 FY2024 | 22% – 22.5% | New |
| Aug 8, 2024 | Adjusted EBITDA margin | Q3 FY2024 | 10.6% – 11.1% | New |
| Aug 8, 2024 | adjusted tax rate | Q3 FY2024 | 27% | Raised |
| Aug 8, 2024 | depreciation | Q3 FY2024 | $20.00M | New |
| Aug 8, 2024 | depreciation in cost of revenue | Q3 FY2024 | $2.00M | Lowered |
| Aug 8, 2024 | non-cash amortization expense | Q3 FY2024 | $22.00M | Raised |
| Aug 8, 2024 | share-based compensation expense | Q3 FY2024 | $6.00M | Lowered |
| Aug 8, 2024 | integration and other expenses | Q3 FY2024 | $6.00M | Reaffirmed |
| Aug 8, 2024 | interest expense | Q3 FY2024 | $15.00M | Raised |
| Aug 8, 2024 | Revenue | Q3 FY2024 | -23% – -20% | New |
| Aug 8, 2024 | Consolidated revenue | Q3 FY2024 | $660.00M – $680.00M | New |
| May 9, 2024 | Gross margin | Q2 FY2024 | 30.7% – 31.2% | New |
| May 9, 2024 | Operating margin | Q2 FY2024 | 3% – 3.7% | New |
| May 9, 2024 | Adjusted EBITDA margin | Q2 FY2024 | 11% – 11.5% | New |
| May 9, 2024 | SG&A as percentage of revenue | Q2 FY2024 | 21.5% – 22% | New |
| May 9, 2024 | Consolidated revenue | Q2 FY2024 | $730.00M – $750.00M | New |
| Feb 15, 2024 | Gross margin | Q1 FY2024 | 31% – 31.5% | New |
| Feb 15, 2024 | Operating margin | Q1 FY2024 | 4.2% – 4.9% | New |
| Feb 15, 2024 | Technology and Workforce Solutions segment revenue | Q1 FY2024 | -20% – -18% | Lowered |
| Feb 15, 2024 | depreciation expense | Q1 FY2024 | $17.00M | New |
| Feb 15, 2024 | depreciation in cost of services | Q1 FY2024 | $2.00M | Lowered |
| Feb 15, 2024 | stock-based compensation expense | Q1 FY2024 | $7.00M | Lowered |
| Feb 15, 2024 | interest expense | Q1 FY2024 | $16.00M | Raised |
| Feb 15, 2024 | integration and other expenses | Q1 FY2024 | $6.00M | Lowered |
| Feb 15, 2024 | non-cash amortization expense | Q1 FY2024 | $25.00M | Raised |
| Feb 15, 2024 | weighted average diluted shares | Q1 FY2024 | 38.2 | New |
| Feb 15, 2024 | SG&A as percentage of revenue | Q1 FY2024 | 21% – 21.5% | New |
| Feb 15, 2024 | Adjusted EBITDA margin | Q1 FY2024 | 11.2% – 11.7% | New |
| Feb 15, 2024 | adjusted tax rate | Q1 FY2024 | 30% | Raised |
| Feb 15, 2024 | Nurse and Allied Solutions segment revenue | Q1 FY2024 | -38% – -36% | New |
| Feb 15, 2024 | Physician and Leadership Solutions segment revenue | Q1 FY2024 | +11% – +14% | Raised |
| Feb 15, 2024 | Consolidated revenue | Q1 FY2024 | -28% – -26% | New |
| Feb 15, 2024 | Consolidated revenue | Q1 FY2024 | $810.00M – $830.00M | New |
| Nov 2, 2023 | Adjusted EBITDA margin | Q4 FY2023 | 12.5% – 13% | New |
| Nov 2, 2023 | Gross margin | Q4 FY2023 | 32.3% – 32.8% | New |
| Nov 2, 2023 | Operating margin | Q4 FY2023 | 5.9% – 6.5% | New |
| Nov 2, 2023 | SG&A as percentage of revenue | Q4 FY2023 | 21% – 21.5% | New |
| Nov 2, 2023 | Consolidated revenue | Q4 FY2023 | $790.00M – $810.00M | New |
| Aug 3, 2023 | Adjusted EBITDA margin | Q3 FY2023 | 14.3% – 14.8% | New |
| Aug 3, 2023 | Gross margin | Q3 FY2023 | 33.3% – 33.8% | New |
| Aug 3, 2023 | Operating margin | Q3 FY2023 | 8.8% – 9.4% | New |
| Aug 3, 2023 | SG&A as percentage of revenue | Q3 FY2023 | 19.8% – 20.3% | New |
| Aug 3, 2023 | Consolidated revenue | Q3 FY2023 | $840.00M – $860.00M | New |
| May 4, 2023 | Adjusted EBITDA margin | Q2 FY2023 | 15.4% – 15.9% | New |
| May 4, 2023 | Gross margin | Q2 FY2023 | 33.4% – 33.9% | New |
| May 4, 2023 | Operating margin | Q2 FY2023 | 10.6% – 11.2% | New |
| May 4, 2023 | SG&A as percentage of revenue | Q2 FY2023 | 19.1% – 19.6% | New |
| Feb 16, 2023 | Adjusted EBITDA margin | Q1 FY2023 | 15.4% – 15.9% | New |
| Feb 16, 2023 | Gross margin | Q1 FY2023 | 32.6% – 33.1% | New |
| Feb 16, 2023 | Operating margin | Q1 FY2023 | 11% – 11.7% | New |
| Feb 16, 2023 | SG&A as percentage of revenue | Q1 FY2023 | 18.3% – 18.8% | New |
| Feb 16, 2023 | Consolidated revenue | Q1 FY2023 | $1.10B – $1.13B | New |
| Nov 3, 2022 | Adjusted EBITDA margin | Q4 FY2022 | 15% – 15.5% | New |
| Nov 3, 2022 | Gross margin | Q4 FY2022 | 33.3% – 33.8% | New |
| Nov 3, 2022 | Operating margin | Q4 FY2022 | 10.7% – 11.3% | New |
| Nov 3, 2022 | SG&A as percentage of revenue | Q4 FY2022 | 19.5% – 20% | New |
| Nov 3, 2022 | Consolidated revenue | Q4 FY2022 | $1.05B – $1.08B | New |
| Aug 4, 2022 | Adjusted EBITDA margin | Q3 FY2022 | 15.5% – 16% | New |
| Aug 4, 2022 | Gross margin | Q3 FY2022 | 33% – 33.5% | New |
| Aug 4, 2022 | Operating margin | Q3 FY2022 | 11.8% – 12.4% | New |
| Aug 4, 2022 | SG&A as percentage of revenue | Q3 FY2022 | 18% – 18.5% | New |
| Aug 4, 2022 | Consolidated revenue | Q3 FY2022 | $1.08B – $1.11B | New |
| May 5, 2022 | Adjusted EBITDA margin | Q2 FY2022 | 15.8% – 16.3% | New |
| May 5, 2022 | Gross margin | Q2 FY2022 | 31.5% – 32% | New |
| May 5, 2022 | Operating margin | Q2 FY2022 | 12.5% – 13% | New |
| May 5, 2022 | SG&A as percentage of revenue | Q2 FY2022 | 16.4% – 16.9% | New |
| May 5, 2022 | Consolidated revenue | Q2 FY2022 | $1.34B – $1.38B | New |
| Feb 17, 2022 | Adjusted EBITDA margin | Q1 FY2022 | 16% – 16.5% | New |
| Feb 17, 2022 | Gross margin | Q1 FY2022 | 31.2% – 31.7% | New |
| Feb 17, 2022 | Operating margin | Q1 FY2022 | 12.9% – 13.4% | New |
| Feb 17, 2022 | SG&A as percentage of revenue | Q1 FY2022 | 15.9% – 16.4% | New |
| Feb 17, 2022 | Consolidated revenue | Q1 FY2022 | $1.48B – $1.52B | New |
| Nov 4, 2021 | Adjusted EBITDA margin | Q4 FY2021 | 15.3% – 15.8% | New |
| Nov 4, 2021 | Gross margin | Q4 FY2021 | 31.8% – 32.3% | New |
| Nov 4, 2021 | Operating margin | Q4 FY2021 | 11.8% – 12.3% | New |
| Nov 4, 2021 | SG&A as percentage of revenue | Q4 FY2021 | 17.5% – 17.9% | New |
| Nov 4, 2021 | Consolidated revenue | Q4 FY2021 | $1.13B – $1.15B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases AMN Healthcare Services filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
See a number that looks wrong?